Setmelanotide vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Imcivree, RM-493
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
Also: Semaglutide + Cagrilintide
A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Key Comparison Insights
- Setmelanotide is FDA approved, while CagriSema remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to CagriSema (Human Trials).
Detailed Comparison
| Attribute | Setmelanotide | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Setmelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. Works downstream of leptin signaling. | Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1. |
| Common Dosing | 2-3 mg daily Once daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection daily | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach. | Phase 3 REDEFINE 1 trial showed 22.7% weight loss at 68 weeks, significantly outperforming semaglutide alone (15.8%). NDA submitted to FDA in December 2025. If approved, expected to become the leading obesity treatment. |
Frequently Asked Questions: Setmelanotide vs CagriSema
What is the difference between Setmelanotide and CagriSema?
Setmelanotide is a weight loss peptide that an mc4r agonist for rare genetic obesity disorders. fda approved for specific gene mutations causing obesity. CagriSema is a weight loss peptide that a combination of semaglutide and cagrilintide (amylin analog). the most effective weight loss drug candidate, showing 22.7% body weight reduction in phase 3 trials - superior to any single-agent glp-1. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Setmelanotide or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. Setmelanotide is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Setmelanotide and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Setmelanotide and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Setmelanotide and CagriSema is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.